Related Experiment Video
Updated: May 6, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Genetic basis of MPN: Beyond JAK2-V617F
Nicole C C Them1, Robert Kralovics
1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT25.3, 1090, Vienna, Austria, nicole.them@cemm.oeaw.ac.at.
Abstract:
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines somatic changes discovered in myeloproliferative neoplasms and how these genetic aberrations influence the pathogenesis of myeloproliferative neoplasms. Furthermore, genetic responses to drug treatments in myeloproliferative neoplasms are discussed.
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pleiotropy
Animal Mitochondrial Genetics
Abnormal Proliferation
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Single Nucleotide Polymorphisms-SNPs

